ANI Pharmaceuticals Announces FDA Approval, Commercial Availability of New 1-mL Vial Size of Purified Cortrophin Gel, For Adjunctive Treatment Of Certain Patients With Acute Gouty Arthritis Flares
Portfolio Pulse from Benzinga Newsdesk
ANI Pharmaceuticals has announced the FDA approval and commercial availability of a new 1-mL vial size of Purified Cortrophin Gel, which is used for the adjunctive treatment of certain patients with acute gouty arthritis flares. This is in addition to the 5-mL vial size that was launched in January 2022.
October 02, 2023 | 10:52 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The FDA approval and commercial availability of a new 1-mL vial size of Purified Cortrophin Gel by ANI Pharmaceuticals could potentially increase the company's market share and revenues.
The FDA approval of a new product or a new version of an existing product is generally a positive development for a pharmaceutical company. It opens up new market opportunities and can lead to increased sales and revenues. In this case, the approval of a new 1-mL vial size of Purified Cortrophin Gel by ANI Pharmaceuticals could potentially increase the company's market share and revenues.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100